Dr. Faltas is currently focused on molecular profiling of metastatic platinum-resistant urothelial bladder carcinoma, a disease with no approved therapies. In particular, he is investigating the molecular changes that occur as urothelial cancer evolves under the effect of chemotherapy and metastatic spread. Identifying these molecular changes will hopefully lead to finding "druggable" targets for translation into therapeutic clinical trials.
The new findings that innate lymphoid cells (ILCs) directly educate T cells in the intestine to not attack beneficial bacteria, and that impairment of ILC function leads to severe intestinal inflammation. Critically, they also demonstrate that loss of MHCII (a type of machinery that delivers signals to T cells) on ILCs is linked to pro-inflammatory cells in patients with IBD (Inflammatory Bowel Disease).
The award, which recognizes major contributions to the advancement of scientific knowledge, was presented to Dr. Patterson at the College's 64th Annual Scientific Session. Dr. Patterson, a Professor of Medicine in the Weill Department of Medicine (WDOM), is the newly recruited Senior Vice President & Chief Operating Officer at NewYork-Presbyterian/Weill Cornell Medical Center.
Membership to the AAP is a coveted honor and reflects remarkable dedication to the advancement of scientific and practical medicine. Founded in 1885 as a non-profit professional organization, the AAP has some 1,300 active members and 600 honorary members.
The Weill Department of Medicine is focused on increasing its research footprint both at Weill Cornell and on a national level. To that end, the department has established a mentoring infrastructure to assist junior faculty during their transition to NIH K and R series grants. This infrastructure supports a monthly meeting that seeks to build, promote, and mentor the department's junior faculty.
Founded in 1908, the American Society of Clinical Investigation is an honor society of some 3,000 physician-scientists who serve in the upper ranks of academic medicine and industry. Those who become members of ASCI are premier leaders in translating findings from the laboratory to the advancement of clinical practice.
Dr. David Artis and colleagues have published breakthrough findings in Nature that have opened a newly targeted pathway, and ultimately, a new approach for the treatment of obesity and obesity-related diseases. Utilizing a wide array of high tech tools, the team discovered for the first time that ILC2s, a group of innate lymphoid cells, promote the "beiging" of white adipose tissue (a type of body fat) and limit obesity.
The investigators concluded that inflammation (studied in the lungs) produces a complex reorganization of cellular and molecular circadian rhythms that are relevant to early events in lung injury, and as distinct from circadian rhythms that occur in healthy lungs. This is an especially noteworthy finding when examined within the broader context of circadian rhythms, which are those daily fluctuations in biological activity that help organisms and human beings adapt to their environment.
Drs. Vivian Bykerk, Lionel B. Ivashkiv, and Alessandra B. Pernis of the Division of Rheumatology will serve as key researchers in one of the 11 research groups across the United States that comprise the NIH Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Network. Rheumatoid Arthritis and Lupus, which can be devastating, are relatively common and severe autoimmune diseases.
Atrial high rate episodes have been associated with an increased risk of stroke, heart failure and death. The study, which officially began in July 2014, has already enrolled six subjects and has recruited multiple leading centers across the United States to participate.
